Stem Cell Therapy advancements, page-427

Bit of news out on stem cells for those interested in the sector, that may account for some surprising intra-day moves in some micro-cap stem cell companies on the ASX today. Ironically more relevant to OCC being specifically about a autologous stem cell treatment, if that is the case:

"Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study"

https://jnnp.bmj.com/content/early/2023/08/14/jnnp-2023-331864

Basically Swedish scientists calling for calling for a stem cell therapy to become standard practice for treating patients with multiple sclerosis. Not related, but coincidentally, another company in the US calling out the FDA on ALS stem cell treatments (I know nothing about that company so would have no idea on its likelihood of success):

https://fortune.com/well/2023/09/25/nurown-fda-review-brainstorm-als-lou-gehrigs-disease/

I've been regularly mocked for saying it, but I post on Hot Copper in part due to the very poor standard of care I received in a tendon rupture repair that OCC's ATI treatment (luckily available under Australia's special access scheme) for me clearly resolved when I had no other real options. It seems the FDA and other regulators increasingly under pressure for their past inflexible approaches with regard to stem cell therapies (the FDA has made changes) from patients with no other real convincing medical options.